Efficacy and safety of double filtration plasmapheresis in combination with interferon therapy for chronic hepatitis C |
| |
Authors: | Shuichi Kaneko Michio Sata Tatsuya Ide Tatsuya Yamashita Shuhei Hige Eiichi Tomita Satoshi Mochida Yukitaka Yamashita Yoshiaki Inui Soo Ryang Kim Naoto Komada Takafumi Mikami Shinichi Satoh Sumiharu Morita Koichi Takaguchi Noboru Hirashima Yuji Nishio Daisuke Watanabe Kiyohide Kioka Kenji Fujiwara |
| |
Institution: | 1. Kanazawa University Graduate School of Medicine, Kanazawa;2. Kurume University School of Medicine, Kurume;3. Hokkaido University Graduate School of Medicine, Sapporo;4. Gifu Municipal Hospital, Gifu;5. Saitama Medical University, Moroyama;6. Japanese Red Cross Wakayama Medical Center, Wakayama;7. Hyogo Prefectural Nishinomiya Hospital, Nishinomiya;8. Kobe Asahi Hospital, Kobe;9. Fujimoto Hayasuzu Hospital, Miyakonojo;10. Kuroishi General Hospital, Kuroishi;11. Seirei Sakura Citizen Hospital, Sakura;12. Miki‐Sanyo Hospital, Miki;13. Kagawa Prefectural Central Hospital, Takamatsu;14. Nagoya Medical Center, Nagoya;15. Meitetsu Hospital, Nagoya;16. Noshiroyamamoto Medical Association Hospital, Noshiro;17. Osaka City General Hospital, Osaka;18. Yokohama Rosai Hospital, Yokohama, Japan |
| |
Abstract: | Aim: Efficacy and safety of double filtration plasmapheresis (DFPP) for chronic hepatitis C were prospectively analyzed in Japanese clinical settings. Methods: All patients who received DFPP in combination with interferon (IFN) therapy for chronic hepatitis C were serially recruited at 36 institutions between April 2008 and July 2009 in Japan. Results: A total of 239 patients were analyzed for the safety of DFPP and 206 patients for the efficacy. Of the 206 patients, 181 patients were treated with DFPP in combination with pegylated interferon plus ribavirin (PEG‐IFN/RBV + DFPP). Among the 181 patients, 60 patients (33.1%) were treatment‐naïves, 35 (19.3%) relapsers and 62 (34.3%) non‐responders. Complete early virological response (cEVR) in patients treated with PEG‐IFN/RBV + DFPP was achieved in 57.5% overall, 70.0% in treatment‐naïves, 57.1% in relapsers and 41.9% in non‐responders. In patients with previous PEG‐IFN/RBV therapy, cEVR were found in 63.0% of relapsers and 18.9 % of non‐responders, and cEVR in patients with other than PEG‐IFN/RBV therapy as previous IFN therapy, relapsers and non‐responders was 37.5% and 76.0%, respectively. Adverse events were found in 55 patients (23.0%). Serious adverse events were found in four patients (1.7%) who showed puncture‐site injury. Adverse events were related to female sex, but not related to age, and DFPP could be performed safely. Conclusion: The cEVR results in this study suggest that high rates of sustained virological response can be achieved in retreated and treatment‐naïve patients using DFPP in combination with PEG‐IFN/RBV therapy. Results indicate that this therapy could be safely conducted, even in elderly patients. |
| |
Keywords: | complete early virological response double filtration plasmapheresis elderly interferon therapy retreated patients treatment‐naï ve patients |
|
|